


11-01-00

CPA/6AM-16148



Attorney Docket No.: 5739.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

RECEIVED

Serial No.: 09/450,609

Group Art Unit: 1614

NOV 02 2000

Filed: November 30, 1999

Examiner: J. Kim

TECH CENTER 1600/2900

For: New Pharmaceutical Composition And The Process For Its Preparation

**FILING OF CONTINUED PROSECUTION
APPLICATION (CPA) UNDER 37 C.F.R. §1.53(d)**

*H1098
50910
11-800*

Commissioner for Patents
Box CPA
Washington, DC 20231

This is a request for filing a continuation application under 37 CFR 1.53(d) of prior application number 09/450,609 filed on November 30, 1999, entitled New Pharmaceutical Composition And The Process For Its Preparation.

1. [x] The filing fee is calculated as follows:

Basic Fee:	\$710.00
Total Claims: 19 - 20 = 0 x 18 =	\$0
Independent Claims: 0 - 3 = 0 x 80 =	\$0
Total Fee:	\$710.00

2. [x] Applicant hereby petitions for an extension of time under 37 CFR 1.136 for three (3) months. If an additional extension of time is required, please consider this a petition therefor. The required extension fee is estimated to be \$890.

3. [x] Please charge the required fee, estimated to be \$1600, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.


Respectfully submitted,

Date: October 31, 2000

Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

11/02/2000 GTEFFERA 00000120 141447 09450609

01 FC:131	710.00 CH
02 FC:117	890.00 CH



Attorney Docket No.: 5739.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Commissioner for Patents
Box CPA
Washington, DC 20231

RECEIVED

NOV 02 2000

TECH CENTER 1600/2900

Re: Continued Prosecution Application of
Serial No. 09/450,609

Sir:

Express Mail Label No. EL 473439791 US

Date of Deposit October 31, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing of Continued Prosecution Application (CPA) under 37 C.F.R. §1.53(d) (in duplicate)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Carol McFarlane

Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123